{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T19:43:49Z","timestamp":1795203829057,"version":"4.10.3"},"reference-count":308,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-026-00703-z","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:01:53Z","timestamp":1780556513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Atopic dermatitis"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-252X","authenticated-orcid":false,"given":"Stephan","family":"Weidinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9304-2212","authenticated-orcid":false,"given":"Sandipan","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ncoza C.","family":"Dlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-0554","authenticated-orcid":false,"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Flohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-2044","authenticated-orcid":false,"given":"Alan D.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"703_CR1","doi-asserted-by":"crossref","unstructured":"Langan, S. M., Irvine, A. D. & Weidinger, S. Atopic dermatitis. Lancet 396, 345\u2013360 (2020).","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"703_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdin.2022.08.026","volume":"11","author":"S Chatrath","year":"2023","unstructured":"Chatrath, S. & Silverberg, J. I. Phenotypic differences of atopic dermatitis stratified by age. JAAD Int. 11, 1\u20137 (2023).","journal-title":"JAAD Int."},{"key":"703_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/bjd\/ljac072","volume":"188","author":"K Abuabara","year":"2023","unstructured":"Abuabara, K. & Langan, S. M. Atopic dermatitis across the life course. Br. J. Dermatol. 188, 709\u2013717 (2023).","journal-title":"Br. J. Dermatol."},{"key":"703_CR4","doi-asserted-by":"crossref","unstructured":"Bosma, A. L. et al. Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics. J. Eur. Acad. Dermatol. Venereol. 36, 807\u2013819 (2022).","DOI":"10.1111\/jdv.18008"},{"key":"703_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.19580","volume":"184","author":"MR Laughter","year":"2021","unstructured":"Laughter, M. R. et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990\u20132017. Br. J. Dermatol. 184, 304\u2013309 (2021).","journal-title":"Br. J. Dermatol."},{"key":"703_CR6","doi-asserted-by":"crossref","unstructured":"Drucker, A. M. et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J. Invest. Dermatol. 137, 26\u201330 (2017).","DOI":"10.1016\/j.jid.2016.07.012"},{"key":"703_CR7","first-page":"587","volume":"29","author":"J Jeskey","year":"2024","unstructured":"Jeskey, J. et al. Atopic dermatitis: a review of diagnosis and treatment. J. Pediatr. Pharmacol. Ther. 29, 587\u2013603 (2024).","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"703_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211002979","volume":"12","author":"G Girolomoni","year":"2021","unstructured":"Girolomoni, G. et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther. Adv. Chronic Dis. 12, 20406223211002979 (2021).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"703_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58310-7","volume":"16","author":"M Oliva","year":"2025","unstructured":"Oliva, M. et al. Integration of GWAS, QTLs and keratinocyte functional assays reveals molecular mechanisms of atopic dermatitis. Nat. Commun. 16, 3101 (2025).","journal-title":"Nat. Commun."},{"key":"703_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41180-2","volume":"14","author":"A Budu-Aggrey","year":"2023","unstructured":"Budu-Aggrey, A. et al. European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation. Nat. Commun. 14, 6172 (2023).","journal-title":"Nat. Commun."},{"key":"703_CR11","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1056\/NEJMra1011040","volume":"365","author":"AD Irvine","year":"2011","unstructured":"Irvine, A. D., McLean, W. H. & Leung, D. Y. Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 365, 1315\u20131327 (2011).","journal-title":"N. Engl. J. Med."},{"key":"703_CR12","unstructured":"Standl, M. et al. Gene-environment interaction affects risk of atopic eczema: population and in vitro studies. Allergy\u00a080, 2201\u20132212 (2025)."},{"key":"703_CR13","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi, L. C. et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J. Invest. Dermatol. 139, 1480\u20131489 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/all.70060","volume":"81","author":"P D\u2019Avino","year":"2026","unstructured":"D\u2019Avino, P. et al. Distinct roles of IL-4, IL-13, and IL-22 in human skin barrier dysfunction and atopic dermatitis. Allergy 81, 480\u2013497 (2026).","journal-title":"Allergy"},{"key":"703_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1101\/gr.131029.111","volume":"22","author":"HH Kong","year":"2012","unstructured":"Kong, H. H. et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 22, 850\u2013859 (2012).","journal-title":"Genome Res."},{"key":"703_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay4068","volume":"12","author":"Y Nakamura","year":"2020","unstructured":"Nakamura, Y. et al. Staphylococcus Agr virulence is critical for epidermal colonization and associates with atopic dermatitis development. Sci. Transl. Med. 12, eaay4068 (2020).","journal-title":"Sci. Transl. Med."},{"key":"703_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jid.2020.05.102","volume":"141","author":"V Moosbrugger-Martinz","year":"2021","unstructured":"Moosbrugger-Martinz, V. et al. Initial evidence of distinguishable bacterial and fungal dysbiosis in the skin of patients with atopic dermatitis or Netherton syndrome. J. Invest. Dermatol. 141, 114\u2013123 (2021).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR18","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jaci.2015.07.052","volume":"137","author":"M Tauber","year":"2016","unstructured":"Tauber, M. et al. Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis. J. Allergy Clin. Immunol. 137, 1272\u20131274.e3 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR19","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.tim.2017.11.008","volume":"26","author":"JA Geoghegan","year":"2018","unstructured":"Geoghegan, J. A., Irvine, A. D. & Foster, T. J. Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship. Trends Microbiol. 26, 484\u2013497 (2018).","journal-title":"Trends Microbiol."},{"key":"703_CR20","doi-asserted-by":"publisher","first-page":"5375","DOI":"10.1016\/j.cell.2023.10.019","volume":"186","author":"L Deng","year":"2023","unstructured":"Deng, L. et al. S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis. Cell 186, 5375\u20135393.e25 (2023).","journal-title":"Cell"},{"key":"703_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","volume":"133","author":"F Cevikbas","year":"2014","unstructured":"Cevikbas, F. et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J. Allergy Clin. Immunol. 133, 448\u2013460 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR22","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jaci.2025.05.011","volume":"156","author":"MK Jha","year":"2025","unstructured":"Jha, M. K. et al. Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch. J. Allergy Clin. Immunol. 156, 1066\u20131081.e12 (2025).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR23","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","volume":"151","author":"JP Thyssen","year":"2023","unstructured":"Thyssen, J. P., Halling, A. S., Schmid-Grendelmeier, P., Guttman-Yassky, E. & Silverberg, J. I. Comorbidities of atopic dermatitis\u2014what does the evidence say?\u00a0J. Allergy Clin. Immunol. 151, 1155\u20131162 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59340-x","volume":"16","author":"A Fukushima-Nomura","year":"2025","unstructured":"Fukushima-Nomura, A. et al. An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis. Nat. Commun. 16, 4981 (2025).","journal-title":"Nat. Commun."},{"key":"703_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaci.2022.02.001","volume":"150","author":"L M\u00f6bus","year":"2022","unstructured":"M\u00f6bus, L. et al. Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis. J. Allergy Clin. Immunol. 150, 385\u2013395 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR26","doi-asserted-by":"crossref","unstructured":"Sekita, A. et al. Multifaceted analysis of cross-tissue transcriptomes reveals phenotype\u2013endotype associations in atopic dermatitis. Nat. Commun. 14, 6133 (2023).","DOI":"10.1038\/s41467-023-41857-8"},{"key":"703_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000370220","volume":"66","author":"S Nutten","year":"2015","unstructured":"Nutten, S. Atopic dermatitis: global epidemiology and risk factors. Ann. Nutr. Metab. 66, 8\u201316 (2015).","journal-title":"Ann. Nutr. Metab."},{"key":"703_CR28","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","volume":"124","author":"JA Odhiambo","year":"2009","unstructured":"Odhiambo, J. A., Williams, H. C., Clayton, T. O., Robertson, C. F. & Asher, M. I. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J. Allergy Clin. Immunol. 124, 1251\u20131258.e23 (2009).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield, L. F. et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J. Am. Acad. Dermatol. 71, 116\u2013132 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","volume":"190","author":"J Tian","year":"2023","unstructured":"Tian, J. et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br. J. Dermatol. 190, 55\u201361 (2023).","journal-title":"Br. J. Dermatol."},{"key":"703_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(06)69283-0","volume":"368","author":"MI Asher","year":"2006","unstructured":"Asher, M. I. et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 368, 733\u2013743 (2006).","journal-title":"Lancet"},{"key":"703_CR32","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jaci.2007.11.004","volume":"121","author":"H Williams","year":"2008","unstructured":"Williams, H. et al. Is eczema really on the increase worldwide?\u00a0J. Allergy Clin. Immunol. 121, 947\u2013954.e15 (2008).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR33","doi-asserted-by":"publisher","unstructured":"Strachan, D., Asher, I., Pearce, N. & Garcia-Marcos, L. International Study of Asthma and Allergies in Childhood 1992-2005 https:\/\/doi.org\/10.5255\/UKDA-SN-8131-1 (UK Data Service, 2017).","DOI":"10.5255\/UKDA-SN-8131-1"},{"key":"703_CR34","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/bjd\/ljaf238","volume":"193","author":"C-Y Chang","year":"2025","unstructured":"Chang, C.-Y. et al. Atopic dermatitis epidemiological research methodology: a global scoping review. Br. J. Dermatol. 193, 830\u2013838 (2025).","journal-title":"Br. J. Dermatol."},{"key":"703_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/all.13946","volume":"75","author":"N Stefanovic","year":"2020","unstructured":"Stefanovic, N., Flohr, C. & Irvine, A. D. The exposome in atopic dermatitis. Allergy 75, 63\u201374 (2020).","journal-title":"Allergy"},{"key":"703_CR36","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1111\/jdv.19193","volume":"37","author":"RP Fadadu","year":"2023","unstructured":"Fadadu, R. P. et al. Air pollution and global healthcare use for atopic dermatitis: a systematic review. J. Eur. Acad. Dermatol. Venereol. 37, 1958\u20131970 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.5414\/ALX02258E","volume":"5","author":"D Luschkova","year":"2021","unstructured":"Luschkova, D., Zeiser, K., Ludwig, A. & Traidl-Hoffmann, C. Atopic eczema is an environmental disease. Allergol. Sel. 5, 244\u2013250 (2021).","journal-title":"Allergol. Sel."},{"key":"703_CR38","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/all.16007","volume":"79","author":"S-P Wang","year":"2024","unstructured":"Wang, S.-P. et al. Impact of climate change on atopic dermatitis: a review by the International Eczema Council. Allergy 79, 1455\u20131469 (2024).","journal-title":"Allergy"},{"key":"703_CR39","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/jid.2013.19","volume":"133","author":"JI Silverberg","year":"2013","unstructured":"Silverberg, J. I., Hanifin, J. & Simpson, E. L. Climatic factors are associated with childhood eczema prevalence in the United States. J. Invest. Dermatol. 133, 1752\u20131759 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/jid.2013.274","volume":"134","author":"MR Sargen","year":"2014","unstructured":"Sargen, M. R., Hoffstad, O. & Margolis, D. J. Warm, humid, and high sun exposure climates are associated with poorly controlled eczema: PEER (Pediatric Eczema Elective Registry) cohort, 2004\u20132012. J. Invest. Dermatol. 134, 51\u201357 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR41","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/all.14304","volume":"75","author":"HA Brough","year":"2020","unstructured":"Brough, H. A. et al. Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented?\u00a0Allergy 75, 2185\u20132205 (2020).","journal-title":"Allergy"},{"key":"703_CR42","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jaci.2020.10.044","volume":"147","author":"MR Perkin","year":"2021","unstructured":"Perkin, M. R. et al. Association of frequent moisturizer use in early infancy with the development of food allergy. J. Allergy Clin. Immunol. 147, 967\u2013976.e1 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR43","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1164\/rccm.202206-1219ED","volume":"206","author":"SC Dharmage","year":"2022","unstructured":"Dharmage, S. C., Lowe, A. J. & Tang, M. L. K. Revisiting the atopic march current evidence. Am. J. Respir. Crit. Care Med. 206, 925\u2013926 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"703_CR44","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jaci.2015.10.049","volume":"137","author":"T Tsakok","year":"2016","unstructured":"Tsakok, T. et al. Does atopic dermatitis cause food allergy? A systematic review. J. Allergy Clin. Immunol. 137, 1071\u20131078 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR45","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3390\/jcm4061217","volume":"4","author":"M Glatz","year":"2015","unstructured":"Glatz, M., Bosshard, P. P., Hoetzenecker, W. & Schmid-Grendelmeier, P. The role of Malassezia spp. in atopic dermatitis. J. Clin. Med. 4, 1217\u20131228 (2015).","journal-title":"J. Clin. Med."},{"key":"703_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.iac.2010.05.001","volume":"30","author":"PY Ong","year":"2010","unstructured":"Ong, P. Y. & Leung, D. Y. The infectious aspects of atopic dermatitis. Immunol. Allergy Clin. N. Am. 30, 309\u2013321 (2010).","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"703_CR47","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jid.2017.01.030","volume":"137","author":"SM Langan","year":"2017","unstructured":"Langan, S. M., Abuabara, K., Henrickson, S. E., Hoffstad, O. & Margolis, D. J. Increased risk of cutaneous and systemic infections in atopic dermatitis\u2014a cohort study. J. Invest. Dermatol. 137, 1375\u20131377 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR48","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.abd.2023.11.003","volume":"99","author":"PR Criado","year":"2024","unstructured":"Criado, P. R. et al. Prurigo: review of its pathogenesis, diagnosis, and treatment. An. Bras. Dermatol. 99, 706\u2013720 (2024).","journal-title":"An. Bras. Dermatol."},{"key":"703_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaci.2025.02.029","volume":"156","author":"N Fyhrquist","year":"2025","unstructured":"Fyhrquist, N., Yang, Y., Karisola, P. & Alenius, H. Endotypes of atopic dermatitis. J. Allergy Clin. Immunol. 156, 24\u201340.e24 (2025).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.02.034","author":"JI Silverberg","year":"2026","unstructured":"Silverberg, J. I. et al. The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: results from a prospective trial. J. Am. Acad. Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2026.02.034 (2026).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/902359","volume":"2015","author":"C Elmose","year":"2015","unstructured":"Elmose, C. & Thomsen, S. F. Twin studies of atopic dermatitis: interpretations and applications in the filaggrin era. J. Allergy 2015, 902359 (2015).","journal-title":"J. Allergy"},{"key":"703_CR52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/ng1767","volume":"38","author":"CN Palmer","year":"2006","unstructured":"Palmer, C. N. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38, 441\u2013446 (2006).","journal-title":"Nat. Genet."},{"key":"703_CR53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.anai.2019.10.008","volume":"124","author":"C Drislane","year":"2020","unstructured":"Drislane, C. & Irvine, A. D. The role of filaggrin in atopic dermatitis and allergic disease. Ann. Allergy Asthma Immunol. 124, 36\u201343 (2020).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"703_CR54","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41590-021-01009-w","volume":"22","author":"S Tuzlak","year":"2021","unstructured":"Tuzlak, S. et al. Repositioning TH cell polarization from single cytokines to complex help. Nat. Immunol. 22, 1210\u20131217 (2021).","journal-title":"Nat. Immunol."},{"key":"703_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw2938","author":"A Bitton","year":"2020","unstructured":"Bitton, A. et al. A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aaw2938 (2020).","journal-title":"Sci. Immunol."},{"key":"703_CR56","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.immuni.2023.03.014","volume":"56","author":"AB Molofsky","year":"2023","unstructured":"Molofsky, A. B. & Locksley, R. M. The ins and outs of innate and adaptive type 2 immunity. Immunity 56, 704\u2013722 (2023).","journal-title":"Immunity"},{"key":"703_CR57","doi-asserted-by":"publisher","first-page":"170ra116","DOI":"10.1126\/scitranslmed.3005374","volume":"5","author":"BS Kim","year":"2013","unstructured":"Kim, B. S. et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci. Transl. Med. 5, 170ra116 (2013).","journal-title":"Sci. Transl. Med."},{"key":"703_CR58","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaci.2021.07.025","volume":"149","author":"N Alkon","year":"2022","unstructured":"Alkon, N. et al. Single-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis. J. Allergy Clin. Immunol. 149, 624\u2013639 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR59","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1084\/jem.20150402","volume":"214","author":"L Pattarini","year":"2017","unstructured":"Pattarini, L. et al. TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand. J. Exp. Med. 214, 1529\u20131546 (2017).","journal-title":"J. Exp. Med."},{"key":"703_CR60","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","volume":"145","author":"LC Tsoi","year":"2020","unstructured":"Tsoi, L. C. et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. J. Allergy Clin. Immunol. 145, 1406\u20131415 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR61","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","volume":"150","author":"M Maurer","year":"2022","unstructured":"Maurer, M. et al. Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis. J. Allergy Clin. Immunol. 150, 1517\u20131524 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR62","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","volume":"80","author":"EL Simpson","year":"2019","unstructured":"Simpson, E. L. et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J. Am. Acad. Dermatol. 80, 1013\u20131021 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR63","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaci.2025.05.007","volume":"156","author":"LD Meesters","year":"2025","unstructured":"Meesters, L. D. et al. Dissecting key contributions of TH2 and TH17 cytokines to atopic dermatitis pathophysiology. J. Allergy Clin. Immunol. 156, 690\u2013704 (2025).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR64","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3810","volume":"101","author":"MAX Tollenaere","year":"2021","unstructured":"Tollenaere, M. A. X. et al. Skin barrier and inflammation genes associated with atopic dermatitis are regulated by interleukin-13 and modulated by tralokinumab in vitro. Acta Derm. Venereol. 101, adv00447 (2021).","journal-title":"Acta Derm. Venereol."},{"key":"703_CR65","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen, L. K. et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 171, 217\u2013228.e3 (2017).","journal-title":"Cell"},{"key":"703_CR66","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg, J. I. et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N. Engl. J. Med. 388, 1080\u20131091 (2023).","journal-title":"N. Engl. J. Med."},{"key":"703_CR67","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg, A. et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br. J. Dermatol. 184, 437\u2013449 (2021).","journal-title":"Br. J. Dermatol."},{"key":"703_CR68","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson, E. L. et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N. Engl. J. Med. 375, 2335\u20132348 (2016).","journal-title":"N. Engl. J. Med."},{"key":"703_CR69","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","volume":"404","author":"JI Silverberg","year":"2024","unstructured":"Silverberg, J. I. et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet 404, 445\u2013460 (2024).","journal-title":"Lancet"},{"key":"703_CR70","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaci.2020.06.012","volume":"147","author":"L M\u00f6bus","year":"2021","unstructured":"M\u00f6bus, L. et al. Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J. Allergy Clin. Immunol. 147, 213\u2013223 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR71","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","volume":"143","author":"PM Brunner","year":"2019","unstructured":"Brunner, P. M. et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J. Allergy Clin. Immunol. 143, 142\u2013154 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR72","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","volume":"136","author":"S Noda","year":"2015","unstructured":"Noda, S. et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J. Allergy Clin. Immunol. 136, 1254\u20131264 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR73","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jaci.2020.04.055","volume":"147","author":"B Ungar","year":"2021","unstructured":"Ungar, B. et al. Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis. J. Allergy Clin. Immunol. 147, 394\u2013397 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR74","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s13555-022-00876-x","volume":"13","author":"SK Tyring","year":"2023","unstructured":"Tyring, S. K. et al. Risankizumab in patients with moderate-to-severe atopic dermatitis: a phase 2, randomized, double-blind, placebo-controlled study. Dermatol. Ther. 13, 595\u2013608 (2023).","journal-title":"Dermatol. Ther."},{"key":"703_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237244","author":"D Tha\u00e7i","year":"2022","unstructured":"Tha\u00e7i, D. et al. Phase 1 and 2 randomized clinical studies determine lack of efficacy for anti-IL-17C antibody MOR106 in moderate-severe atopic dermatitis. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm11237244 (2022).","journal-title":"J. Clin. Med."},{"key":"703_CR76","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/bjd\/ljae230","volume":"191","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky, E. et al. The role of OX40 ligand\/OX40 axis signalling in atopic dermatitis. Br. J. Dermatol. 191, 488\u2013496 (2024).","journal-title":"Br. J. Dermatol."},{"key":"703_CR77","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","volume":"401","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky, E. et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet 401, 204\u2013214 (2023).","journal-title":"Lancet"},{"key":"703_CR78","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","volume":"155","author":"S Weidinger","year":"2025","unstructured":"Weidinger, S. et al. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J. Allergy Clin. Immunol. 155, 1264\u20131275 (2025).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR79","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jaci.2012.02.002","volume":"129","author":"TS Tang","year":"2012","unstructured":"Tang, T. S., Bieber, T. & Williams, H. C. Does \u201cautoreactivity\u201d play a role in atopic dermatitis?\u00a0J. Allergy Clin. Immunol. 129, 1209\u20131215.e2 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR80","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/jid.2014.25","volume":"134","author":"S Hradetzky","year":"2014","unstructured":"Hradetzky, S. et al. Cytokine effects induced by the human autoallergen alpha-NAC. J. Invest. Dermatol. 134, 1570\u20131578 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR81","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.jid.2023.01.040","volume":"143","author":"C Bangert","year":"2023","unstructured":"Bangert, C. et al. IgE depletion with ligelizumab does not significantly improve clinical symptoms in patients with moderate-to-severe atopic dermatitis. J. Invest. Dermatol. 143, 1896\u20131905.e8 (2023).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR82","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.jaci.2016.05.038","volume":"138","author":"HH Wang","year":"2016","unstructured":"Wang, H. H., Li, Y. C. & Huang, Y. C. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J. Allergy Clin. Immunol. 138, 1719\u20131722.e1 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR83","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaci.2024.10.027","volume":"155","author":"S Scharli","year":"2025","unstructured":"Sch\u00e4rli, S. et al. IL-9 sensitizes human TH2 cells to proinflammatory IL-18 signals in atopic dermatitis. J. Allergy Clin. Immunol. 155, 491\u2013504.e9 (2025).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR84","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jaci.2023.11.017","volume":"153","author":"L Migayron","year":"2024","unstructured":"Migayron, L., Merhi, R., Seneschal, J. & Boniface, K. Resident memory T cells in nonlesional skin and healed lesions of patients with chronic inflammatory diseases: appearances can be deceptive. J. Allergy Clin. Immunol. 153, 606\u2013614 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100277","volume":"4","author":"JA Daccache","year":"2024","unstructured":"Daccache, J. A. & Naik, S. Inflammatory memory in chronic skin disease. JID Innov. 4, 100277 (2024).","journal-title":"JID Innov."},{"key":"703_CR86","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cell.2020.12.033","volume":"184","author":"F Wang","year":"2021","unstructured":"Wang, F. et al. A basophil-neuronal axis promotes itch. Cell 184, 422\u2013440.e17 (2021).","journal-title":"Cell"},{"key":"703_CR87","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/ni.3614","volume":"18","author":"T Hidaka","year":"2017","unstructured":"Hidaka, T. et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. Nat. Immunol. 18, 64\u201373 (2017).","journal-title":"Nat. Immunol."},{"key":"703_CR88","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1917006","volume":"383","author":"K Kabashima","year":"2020","unstructured":"Kabashima, K., Matsumura, T., Komazaki, H. & Kawashima, M. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N. Engl. J. Med. 383, 141\u2013150 (2020).","journal-title":"N. Engl. J. Med."},{"key":"703_CR89","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.jid.2024.01.011","volume":"144","author":"S Saheb Kashaf","year":"2024","unstructured":"Saheb Kashaf, S. & Kong, H. H. Adding fuel to the fire? The skin microbiome in atopic dermatitis. J. Invest. Dermatol. 144, 969\u2013977 (2024).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR90","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.jaci.2018.01.019","volume":"141","author":"H Baurecht","year":"2018","unstructured":"Baurecht, H. et al. Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. J. Allergy Clin. Immunol. 141, 1668\u20131676.e1616 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR91","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jaci.2016.07.029","volume":"139","author":"EA Kennedy","year":"2017","unstructured":"Kennedy, E. A. et al. Skin microbiome before development of atopic dermatitis: early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. J. Allergy Clin. Immunol. 139, 166\u2013172 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR92","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/jdv.19932","volume":"38","author":"M Fonfara","year":"2024","unstructured":"Fonfara, M. et al. Stratum corneum and microbial biomarkers precede and characterize childhood atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 38, 1769\u20131775 (2024).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100131","volume":"2","author":"LA Beck","year":"2022","unstructured":"Beck, L. A. et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innov. 2, 100131 (2022).","journal-title":"JID Innov."},{"key":"703_CR94","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1111\/all.15742","volume":"78","author":"J Hartmann","year":"2023","unstructured":"Hartmann, J. et al. Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis. Allergy 78, 2290\u20132300 (2023).","journal-title":"Allergy"},{"key":"703_CR95","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/bjd\/ljae138","volume":"191","author":"N Sander","year":"2024","unstructured":"Sander, N. et al. Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis. Br. J. Dermatol. 191, 344\u2013350 (2024).","journal-title":"Br. J. Dermatol."},{"key":"703_CR96","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaci.2023.05.026","volume":"152","author":"EL Simpson","year":"2023","unstructured":"Simpson, E. L. et al. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment. J. Allergy Clin. Immunol. 152, 1179\u20131195 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.07.006","author":"T Thomova","year":"2025","unstructured":"Thomova, T. et al. Effect of systemic therapies on skin bacteriome in patients with atopic dermatitis: a pilot prospective study. J. Invest. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2025.07.006 (2025).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR98","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.chom.2019.02.002","volume":"25","author":"F Sparber","year":"2019","unstructured":"Sparber, F. et al. The skin commensal yeast Malassezia triggers a type 17 response that coordinates anti-fungal immunity and exacerbates skin inflammation. Cell Host Microbe 25, 389\u2013403.e6 (2019).","journal-title":"Cell Host Microbe"},{"key":"703_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1114321","volume":"14","author":"H Chu","year":"2023","unstructured":"Chu, H. et al. Head and neck dermatitis is exacerbated by Malassezia furfur colonization, skin barrier disruption, and immune dysregulation. Front. Immunol. 14, 1114321 (2023).","journal-title":"Front. Immunol."},{"key":"703_CR100","doi-asserted-by":"publisher","DOI":"10.1093\/femsyr\/foad028","author":"DE Corzo Leon","year":"2023","unstructured":"Corzo Leon, D. E., Scheynius, A., MacCallum, D. M. & Munro, C. A. Malassezia sympodialis Mala s 1 allergen is a potential KELCH protein that cross reacts with human skin. FEMS Yeast Res. https:\/\/doi.org\/10.1093\/femsyr\/foad028 (2023).","journal-title":"FEMS Yeast Res."},{"key":"703_CR101","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15108","volume":"33","author":"HX See Tow","year":"2024","unstructured":"See Tow, H. X. & Yew, Y. W. Malassezia specific IgE in head and neck dermatitis of eczema: a systematic review & meta-analysis. Exp. Dermatol. 33, e15108 (2024).","journal-title":"Exp. Dermatol."},{"key":"703_CR102","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12016-024-09000-7","volume":"66","author":"AC Chong","year":"2024","unstructured":"Chong, A. C., Navarro-Trivi\u00f1o, F. J., Su, M. & Park, C. O. Fungal head and neck dermatitis: current understanding and management. Clin. Rev. Allergy Immunol. 66, 363\u2013375 (2024).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"703_CR103","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo, C. E. et al. Facial and neck erythema associated with dupilumab treatment: a systematic review. J. Am. Acad. Dermatol. 84, 1339\u20131347 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR104","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/bjd.21019","volume":"186","author":"E Kozera","year":"2022","unstructured":"Kozera, E., Stewart, T., Gill, K., De La Vega, M. A. & Frew, J. W. Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study. Br. J. Dermatol. 186, 1050\u20131052 (2022).","journal-title":"Br. J. Dermatol."},{"key":"703_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100279","volume":"4","author":"ND Jackson","year":"2024","unstructured":"Jackson, N. D. et al. Atopic dermatitis complicated by recurrent eczema herpeticum is characterized by multiple, concurrent epidermal inflammatory endotypes. JID Innov. 4, 100279 (2024).","journal-title":"JID Innov."},{"key":"703_CR106","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.jaci.2023.08.024","volume":"152","author":"S Traidl","year":"2023","unstructured":"Traidl, S. et al. Dupilumab strengthens herpes simplex virus type 1-specific immune responses in atopic dermatitis. J. Allergy Clin. Immunol. 152, 1460\u20131469.e5 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR107","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(05)65206-3","volume":"348","author":"MJ Rothe","year":"1996","unstructured":"Rothe, M. J. & Grant-Kels, J. M. Diagnostic criteria for atopic dermatitis. Lancet 348, 769\u2013770 (1996).","journal-title":"Lancet"},{"key":"703_CR108","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1046\/j.0022-202x.2001.01579.x","volume":"117","author":"S Fleming","year":"2001","unstructured":"Fleming, S. et al. An application of the United Kingdom working party diagnostic criteria for atopic dermatitis in Scottish infants. J. Invest. Dermatol. 117, 1526\u20131530 (2001).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR109","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4103\/idoj.idoj_192_22","volume":"14","author":"NS Shetty","year":"2023","unstructured":"Shetty, N. S., Lunge, S., Sardesai, V. R. & Dalal, A. B. A cross-sectional study comparing application of Hanifin and Rajka criteria in Indian pediatric atopic dermatitis patients to that of other countries. Indian. Dermatol. Online J. 14, 32\u201337 (2023).","journal-title":"Indian. Dermatol. Online J."},{"key":"703_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/1471-5945-10-11","volume":"10","author":"A Strina","year":"2010","unstructured":"Strina, A. et al. Validation of epidemiological tools for eczema diagnosis in Brazilian children: the ISAAC\u2019s and UK Working Party\u2019s criteria. BMC Dermatol. 10, 11 (2010).","journal-title":"BMC Dermatol."},{"key":"703_CR111","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19831","volume":"186","author":"KMA Endre","year":"2022","unstructured":"Endre, K. M. A. et al. Diagnosing atopic dermatitis in infancy using established diagnostic criteria: a cohort study. Br. J. Dermatol. 186, 50\u201358 (2022).","journal-title":"Br. J. Dermatol."},{"key":"703_CR112","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1046\/j.1365-2133.2002.04965.x","volume":"147","author":"MA Ben-Gashir","year":"2002","unstructured":"Ben-Gashir, M. A. & Hay, R. J. Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts. Br. J. Dermatol. 147, 920\u2013925 (2002).","journal-title":"Br. J. Dermatol."},{"key":"703_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072701","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi, A., Maurelli, M., Calabrese, L., Peris, K. & Girolomoni, G. Overview of atopic dermatitis in different ethnic groups. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm12072701 (2023).","journal-title":"J. Clin. Med."},{"key":"703_CR114","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jaip.2023.03.041","volume":"11","author":"CM Davis","year":"2023","unstructured":"Davis, C. M., Flohr, C., Gupta, M. R. & Koplin, J. J. Managing atopic dermatitis in patients with skin of color. J. Allergy Clin. Immunol. Pract. 11, 1376\u20131383 (2023).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"703_CR115","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","volume":"122","author":"RD Sanyal","year":"2019","unstructured":"Sanyal, R. D. et al. Atopic dermatitis in African American patients is TH2\/TH22-skewed with TH1\/TH17 attenuation. Ann. Allergy Asthma Immunol. 122, 99\u2013110.e6 (2019).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"703_CR116","first-page":"23","volume":"186","author":"European Task Force on Atopic Dermatitis","year":"1993","unstructured":"European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 186, 23\u201331 (1993).","journal-title":"Dermatology"},{"key":"703_CR117","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin, J. M. et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI evaluator group. Exp. Dermatol. 10, 11\u201318 (2001).","journal-title":"Exp. Dermatol."},{"key":"703_CR118","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","volume":"33","author":"JM Hanifin","year":"2022","unstructured":"Hanifin, J. M. The eczema area and severity index\u2014a practical guide. Dermatitis 33, 187\u2013192 (2022).","journal-title":"Dermatitis"},{"key":"703_CR119","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/jdv.15999","volume":"34","author":"O Faye","year":"2020","unstructured":"Faye, O. et al. Validation of the patient-oriented scoring for atopic dermatitis tool for black skin. J. Eur. Acad. Dermatol. Venereol. 34, 795\u2013799 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR120","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman, C. R., Venn, A. J. & Williams, H. C. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch. Dermatol. 140, 1513\u20131519 (2004).","journal-title":"Arch. Dermatol."},{"key":"703_CR121","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/j.1398-9995.2011.02577.x","volume":"66","author":"JF Stalder","year":"2011","unstructured":"Stalder, J. F. et al. Patient-oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy 66, 1114\u20131121 (2011).","journal-title":"Allergy"},{"key":"703_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010217","author":"H-Y Huang","year":"2024","unstructured":"Huang, H.-Y. Identification of skin lesions by snapshot hyperspectral imaging. Cancers https:\/\/doi.org\/10.3390\/cancers16010217 (2024).","journal-title":"Cancers"},{"key":"703_CR123","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2484665","volume":"57","author":"F Cao","year":"2025","unstructured":"Cao, F. et al. Advancements in artificial intelligence for atopic dermatitis: diagnosis, treatment, and patient management. Ann. Med. 57, 2484665 (2025).","journal-title":"Ann. Med."},{"key":"703_CR124","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/all.13763","volume":"74","author":"T Haahtela","year":"2019","unstructured":"Haahtela, T. A biodiversity hypothesis. Allergy 74, 1445\u20131456 (2019).","journal-title":"Allergy"},{"key":"703_CR125","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jacig.2022.06.002","volume":"1","author":"AB Wyss","year":"2022","unstructured":"Wyss, A. B. et al. Early-life farm exposures and eczema among adults in the Agricultural Lung Health Study. J. Allergy Clin. Immunol. Glob. 1, 248\u2013256 (2022).","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"703_CR126","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s13555-019-0285-2","volume":"9","author":"KAM Al-Afif","year":"2019","unstructured":"Al-Afif, K. A. M. et al. Understanding the burden of atopic dermatitis in Africa and the Middle East. Dermatol. Ther. 9, 223\u2013241 (2019).","journal-title":"Dermatol. Ther."},{"key":"703_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.613906","volume":"9","author":"T Baars","year":"2021","unstructured":"Baars, T., Wold, A., Vuitton, D. A., Garssen, J. & Berge, A. C. Raw cow milk consumption and the atopic march. Front. Pediatr. 9, 613906 (2021).","journal-title":"Front. Pediatr."},{"key":"703_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030553","author":"AI Nekrasova","year":"2024","unstructured":"Nekrasova, A. I. et al. Characteristics of the gut microbiota in regard to atopic dermatitis and food allergies of children. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines12030553 (2024).","journal-title":"Biomedicines"},{"key":"703_CR129","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jaci.2020.09.042","volume":"147","author":"T Marrs","year":"2021","unstructured":"Marrs, T. et al. Gut microbiota development during infancy: impact of introducing allergenic foods. J. Allergy Clin. Immunol. 147, 613\u2013621.e9 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021055","author":"F Inchingolo","year":"2024","unstructured":"Inchingolo, F. et al. The impact of cesarean section delivery on intestinal microbiota: mechanisms, consequences, and perspectives\u2014a systematic review. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25021055 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"703_CR131","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/bjd.12476","volume":"169","author":"T Tsakok","year":"2013","unstructured":"Tsakok, T., McKeever, T. M., Yeo, L. & Flohr, C. Does early life exposure to antibiotics increase the risk of eczema? A systematic review. Br. J. Dermatol. 169, 983\u2013991 (2013).","journal-title":"Br. J. Dermatol."},{"key":"703_CR132","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1001\/jamapediatrics.2017.0378","volume":"171","author":"PS Pannaraj","year":"2017","unstructured":"Pannaraj, P. S. et al. Association between breast milk bacterial communities and establishment and development of the infant gut microbiome. JAMA Pediatr. 171, 647\u2013654 (2017).","journal-title":"JAMA Pediatr."},{"key":"703_CR133","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.4064","volume":"172","author":"C Flohr","year":"2018","unstructured":"Flohr, C. et al. Effect of an intervention to promote breastfeeding on asthma, lung function, and atopic eczema at age 16 years: follow-up of the PROBIT randomized trial. JAMA Pediatr. 172, e174064 (2018).","journal-title":"JAMA Pediatr."},{"key":"703_CR134","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1080\/09546634.2022.2091101","volume":"33","author":"L Chen","year":"2022","unstructured":"Chen, L., Ni, Y., Wu, X. & Chen, G. Probiotics for the prevention of atopic dermatitis in infants from different geographic regions: a systematic review and meta-analysis. J. Dermatol. Treat. 33, 2931\u20132939 (2022).","journal-title":"J. Dermatol. Treat."},{"key":"703_CR135","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/pai.13514","volume":"32","author":"CSC Tan-Lim","year":"2021","unstructured":"Tan-Lim, C. S. C. et al. Comparative effectiveness of probiotic strains on the prevention of pediatric atopic dermatitis: a systematic review and network meta-analysis. Pediatr. Allergy Immunol. 32, 1255\u20131270 (2021).","journal-title":"Pediatr. Allergy Immunol."},{"key":"703_CR136","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jid.2024.02.021","volume":"144","author":"AS Paller","year":"2024","unstructured":"Paller, A. S., Scharschmidt, T. C., Kezic, S. & Irvine, A. D. Preclinical atopic dermatitis skin in infants: an emerging research area. J. Invest. Dermatol. 144, 1001\u20131009 (2024).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR137","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/cea.13847","volume":"51","author":"MM Kelleher","year":"2021","unstructured":"Kelleher, M. M. et al. Skincare interventions in infants for preventing eczema and food allergy: a Cochrane systematic review and individual participant data meta-analysis. Clin. Exp. Allergy 51, 402\u2013418 (2021).","journal-title":"Clin. Exp. Allergy"},{"key":"703_CR138","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/all.15491","volume":"78","author":"C N\u00ed Chaoimh","year":"2023","unstructured":"N\u00ed Chaoimh, C. et al. Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants\u2014the STOP-AD randomised controlled trial. Allergy 78, 984\u2013994 (2023).","journal-title":"Allergy"},{"key":"703_CR139","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jaad.2009.11.011","volume":"63","author":"EL Simpson","year":"2010","unstructured":"Simpson, E. L., Berry, T. M., Brown, P. A. & Hanifin, J. M. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J. Am. Acad. Dermatol. 63, 587\u2013593 (2010).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR140","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/cea.13797","volume":"51","author":"ZK Jabbar-Lopez","year":"2021","unstructured":"Jabbar-Lopez, Z. K. et al. The effect of water hardness on atopic eczema, skin barrier function: a systematic review, meta-analysis. Clin. Exp. Allergy 51, 430\u2013451 (2021).","journal-title":"Clin. Exp. Allergy"},{"key":"703_CR141","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jid.2017.08.037","volume":"138","author":"SG Danby","year":"2018","unstructured":"Danby, S. G. et al. The effect of water hardness on surfactant deposition after washing and subsequent skin irritation in atopic dermatitis patients and healthy control subjects. J. Invest. Dermatol. 138, 68\u201377 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR142","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/cea.14071","volume":"52","author":"ZK Jabbar-Lopez","year":"2022","unstructured":"Jabbar-Lopez, Z. K. et al. Randomized controlled pilot trial with ion-exchange water softeners to prevent eczema (SOFTER trial). Clin. Exp. Allergy 52, 405\u2013415 (2022).","journal-title":"Clin. Exp. Allergy"},{"key":"703_CR143","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/jamadermatol.2015.0250","volume":"151","author":"GC Mohan","year":"2015","unstructured":"Mohan, G. C. & Lio, P. A. Comparison of dermatology and allergy guidelines for atopic dermatitis management. JAMA Dermatol. 151, 1009\u20131013 (2015).","journal-title":"JAMA Dermatol."},{"key":"703_CR144","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/1744666X.2016.1212660","volume":"13","author":"R Kantor","year":"2017","unstructured":"Kantor, R. & Silverberg, J. I. Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev. Clin. Immunol. 13, 15\u201326 (2017).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"703_CR145","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.jid.2017.11.040","volume":"138","author":"K Yamaga","year":"2018","unstructured":"Yamaga, K. et al. Claudin-3 loss causes leakage of sweat from the sweat gland to contribute to the pathogenesis of atopic dermatitis. J. Invest. Dermatol. 138, 1279\u20131287 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR146","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.alit.2018.06.003","volume":"67","author":"H Murota","year":"2018","unstructured":"Murota, H., Yamaga, K., Ono, E. & Katayama, I. Sweat in the pathogenesis of atopic dermatitis. Allergol. Int. 67, 455\u2013459 (2018).","journal-title":"Allergol. Int."},{"key":"703_CR147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175229","volume":"12","author":"YM Kim","year":"2017","unstructured":"Kim, Y. M. et al. Short-term effects of weather and air pollution on atopic dermatitis symptoms in children: a panel study in Korea. PLoS ONE 12, e0175229 (2017).","journal-title":"PLoS ONE"},{"key":"703_CR148","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jdin.2022.08.004","volume":"9","author":"HA Ram\u00edrez-Mar\u00edn","year":"2022","unstructured":"Ram\u00edrez-Mar\u00edn, H. A., Singh, A. M., Ong, P. Y. & Silverberg, J. I. Food allergy testing in atopic dermatitis. JAAD Int. 9, 50\u201356 (2022).","journal-title":"JAAD Int."},{"key":"703_CR149","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1414850","volume":"372","author":"G Du Toit","year":"2015","unstructured":"Du Toit, G. et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N. Engl. J. Med. 372, 803\u2013813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"703_CR150","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJMoa1514210","volume":"374","author":"MR Perkin","year":"2016","unstructured":"Perkin, M. R. et al. Randomized trial of introduction of allergenic foods in breast-fed infants. N. Engl. J. Med. 374, 1733\u20131743 (2016).","journal-title":"N. Engl. J. Med."},{"key":"703_CR151","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jaci.2015.04.015","volume":"136","author":"T Werfel","year":"2015","unstructured":"Werfel, T. et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J. Allergy Clin. Immunol. 136, 96\u2013103.e9 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR152","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jdv.13599","volume":"30","author":"A Wollenberg","year":"2016","unstructured":"Wollenberg, A. et al. ETFAD\/EADV Eczema Task Force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J. Eur. Acad. Dermatol. Venereol. 30, 729\u2013747 (2016).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR153","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/jdv.20639","volume":"39","author":"A Wollenberg","year":"2025","unstructured":"Wollenberg, A. et al. European guideline (EuroGuiDerm) on atopic eczema: living update. J. Eur. Acad. Dermatol. Venereol. 39, 1537\u20131566 (2025).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR154","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/jdv.18429","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg, A. et al. European guideline (EuroGuiDerm) on atopic eczema \u2014 part II: non-systemic treatments and treatment recommendations for special AE patient populations. J. Eur. Acad. Dermatol. Venereol. 36, 1904\u20131926 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR155","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis, D. M. R. et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J. Am. Acad. Dermatol. 90, e43\u2013e56 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR156","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury, R. et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J. Am. Acad. Dermatol. 89, e1\u2013e20 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR157","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1111\/1346-8138.17544","volume":"52","author":"H Saeki","year":"2025","unstructured":"Saeki, H. et al. English version of clinical practice guidelines for the management of atopic dermatitis 2024. J. Dermatol. 52, e70\u2013e142 (2025).","journal-title":"J. Dermatol."},{"key":"703_CR158","first-page":"307","volume":"22","author":"T Werfel","year":"2024","unstructured":"Werfel, T. et al. S3 guideline atopic dermatitis: part 2 - systemic treatment. J. Dtsch. Dermatol. Ges. 22, 307\u2013320 (2024).","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"703_CR159","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg, A. et al. European guideline (EuroGuiDerm) on atopic eczema: part I \u2014 systemic therapy. J. Eur. Acad. Dermatol. Venereol. 36, 1409\u20131431 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR160","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s13555-025-01589-7","volume":"16","author":"E Papadimitropoulos","year":"2026","unstructured":"Papadimitropoulos, E. et al. Burden, treatment patterns and real-world barriers to prescribing advanced treatments in adults with atopic dermatitis in Brazil and Colombia. Dermatol. Ther. 16, 451\u2013472 (2026).","journal-title":"Dermatol. Ther."},{"key":"703_CR161","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/bjd\/ljad042","volume":"188","author":"A Mosam","year":"2023","unstructured":"Mosam, A. & Todd, G. Global epidemiology and disparities in atopic dermatitis. Br. J. Dermatol. 188, 726\u2013737 (2023).","journal-title":"Br. J. Dermatol."},{"key":"703_CR162","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/ijd.17793","volume":"64","author":"A Wollenberg","year":"2025","unstructured":"Wollenberg, A., Barbarot, S. & Torrelo, A. Basic emollients for xerosis cutis in atopic dermatitis: a review of clinical studies. Int. J. Dermatol. 64, 13\u201328 (2025).","journal-title":"Int. J. Dermatol."},{"key":"703_CR163","volume":"2","author":"EJ van Zuuren","year":"2017","unstructured":"van Zuuren, E. J., Fedorowicz, Z., Christensen, R., Lavrijsen, A. & Arents, B. W. M. Emollients and moisturisers for eczema. Cochrane Database Syst. Rev. 2, Cd012119 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"703_CR164","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.anai.2022.01.012","volume":"128","author":"PM Elias","year":"2022","unstructured":"Elias, P. M. Optimizing emollient therapy for skin barrier repair in atopic dermatitis. Ann. Allergy Asthma Immunol. 128, 505\u2013511 (2022).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"703_CR165","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ijd.17790","volume":"64","author":"JW Fluhr","year":"2025","unstructured":"Fluhr, J. W., Muguet, V. & Christen-Zaech, S. Restoring skin hydration and barrier function: mechanistic insights into basic emollients for xerosis cutis. Int. J. Dermatol. 64, 5\u201312 (2025).","journal-title":"Int. J. Dermatol."},{"key":"703_CR166","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3310\/hta22570","volume":"22","author":"M Santer","year":"2018","unstructured":"Santer, M. et al. Adding emollient bath additives to standard eczema management for children with eczema: the BATHE RCT. Health Technol. Assess. 22, 57 (2018).","journal-title":"Health Technol. Assess."},{"key":"703_CR167","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00403-020-02164-0","volume":"313","author":"T Hua","year":"2021","unstructured":"Hua, T. et al. Does daily bathing or showering worsen atopic dermatitis severity? A systematic review and meta-analysis. Arch. Dermatol. Res. 313, 729\u2013735 (2021).","journal-title":"Arch. Dermatol. Res."},{"key":"703_CR168","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jaip.2019.10.042","volume":"8","author":"ID Cardona","year":"2020","unstructured":"Cardona, I. D., Kempe, E. E., Lary, C., Ginder, J. H. & Jain, N. Frequent versus infrequent bathing in pediatric atopic dermatitis: a randomized clinical trial. J. Allergy Clin. Immunol. Pract. 8, 1014\u20131021 (2020).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"703_CR169","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/bjd\/ljaf451","volume":"194","author":"NE van Hout","year":"2026","unstructured":"van Hout, N. E. et al. From prebiotics to engineered microbes: microbe-inspired treatments for atopic dermatitis. Br. J. Dermatol. 194, 420 (2026).","journal-title":"Br. J. Dermatol."},{"key":"703_CR170","volume":"8","author":"SJ Lax","year":"2024","unstructured":"Lax, S. J. et al. Topical anti-inflammatory treatments for eczema: network meta-analysis. Cochrane Database Syst. Rev. 8, Cd015064 (2024).","journal-title":"Cochrane Database Syst. Rev."},{"key":"703_CR171","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","volume":"152","author":"DK Chu","year":"2023","unstructured":"Chu, D. K. et al. Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J. Allergy Clin. Immunol. 152, 1493\u20131519 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR172","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000489125","volume":"89","author":"LK Wood Heickman","year":"2018","unstructured":"Wood Heickman, L. K., Davallow Ghajar, L., Conaway, M. & Rogol, A. D. Evaluation of hypothalamic-pituitary-adrenal axis suppression following cutaneous use of topical corticosteroids in children: a meta-analysis. Horm. Res. Paediatr. 89, 389\u2013396 (2018).","journal-title":"Horm. Res. Paediatr."},{"key":"703_CR173","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40257-021-00623-6","volume":"22","author":"M Contento","year":"2021","unstructured":"Contento, M., Cline, A. & Russo, M. Steroid phobia: a review of prevalence, risk factors, and interventions. Am. J. Clin. Dermatol. 22, 837\u2013851 (2021).","journal-title":"Am. J. Clin. Dermatol."},{"key":"703_CR174","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2133.2010.10030.x","volume":"164","author":"J Schmitt","year":"2011","unstructured":"Schmitt, J., von Kobyletzki, L., Svensson, A. & Apfelbacher, C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br. J. Dermatol. 164, 415\u2013428 (2011).","journal-title":"Br. J. Dermatol."},{"key":"703_CR175","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2014.11.024","volume":"72","author":"T Hajar","year":"2015","unstructured":"Hajar, T. et al. A systematic review of topical corticosteroid withdrawal (\u201csteroid addiction\u201d) in patients with atopic dermatitis and other dermatoses. J. Am. Acad. Dermatol. 72, 541\u2013549.e2 (2015).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR176","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jaip.2023.03.022","volume":"11","author":"J Pena","year":"2023","unstructured":"Pena, J., Zameza, P. A., Pixley, J. N., Remitz, A. & Feldman, S. R. A comparison of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis. J. Allergy Clin. Immunol. Pract. 11, 1347\u20131359 (2023).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"703_CR177","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller, A. S. et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J. Am. Acad. Dermatol. 75, 494\u2013503.e6 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR178","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40257-023-00780-w","volume":"24","author":"LF Eichenfield","year":"2023","unstructured":"Eichenfield, L. F. et al. Once-daily crisaborole ointment, 2%, as a long-term maintenance treatment in patients aged \u22653 months with mild-to-moderate atopic dermatitis: a 52-week clinical study. Am. J. Clin. Dermatol. 24, 623\u2013635 (2023).","journal-title":"Am. J. Clin. Dermatol."},{"key":"703_CR179","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jaad.2017.06.010","volume":"77","author":"LF Eichenfield","year":"2017","unstructured":"Eichenfield, L. F. et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J. Am. Acad. Dermatol. 77, 641\u2013649.e5 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR180","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamadermatol.2024.3121","volume":"160","author":"EL Simpson","year":"2024","unstructured":"Simpson, E. L. et al. Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials. JAMA Dermatol. 160, 1161\u20131170 (2024).","journal-title":"JAMA Dermatol."},{"key":"703_CR181","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp, K. et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J. Am. Acad. Dermatol. 85, 863\u2013872 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR182","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","volume":"145","author":"BS Kim","year":"2020","unstructured":"Kim, B. S. et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream. J. Allergy Clin. Immunol. 145, 572\u2013582 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR183","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaad.2025.05.1385","volume":"93","author":"LF Eichenfield","year":"2025","unstructured":"Eichenfield, L. F. et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: results from TRuE-AD3, a phase 3, randomized double-blind study. J. Am. Acad. Dermatol. 93, 689\u2013698 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR184","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","volume":"82","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa, H. et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J. Am. Acad. Dermatol. 82, 823\u2013831 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR185","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/1346-8138.15173","volume":"47","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa, H. et al. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J. Dermatol. 47, 114\u2013120 (2020).","journal-title":"J. Dermatol."},{"key":"703_CR186","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","volume":"85","author":"H Nakagawa","year":"2021","unstructured":"Nakagawa, H. et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J. Am. Acad. Dermatol. 85, 854\u2013862 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR187","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2023.12.013","volume":"154","author":"JI Silverberg","year":"2024","unstructured":"Silverberg, J. I. et al. Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: a clinical review. J. Allergy Clin. Immunol. 154, 1\u201310 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR188","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg, J. I. et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J. Am. Acad. Dermatol. 91, 457\u2013465 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR189","volume":"10","author":"AH Musters","year":"2021","unstructured":"Musters, A. H. et al. Phototherapy for atopic eczema. Cochrane Database Syst. Rev. 10, Cd013870 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"key":"703_CR190","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11882-024-01145-x","volume":"24","author":"HJ Yim","year":"2024","unstructured":"Yim, H. J., Jean, T. & Ong, P. Y. Comparison of old and new systemic treatments for moderate to severe atopic dermatitis. Curr. Allergy Asthma Rep. 24, 289\u2013301 (2024).","journal-title":"Curr. Allergy Asthma Rep."},{"key":"703_CR191","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","volume":"133","author":"E Roekevisch","year":"2014","unstructured":"Roekevisch, E., Spuls, P. I., Kuester, D., Limpens, J. & Schmitt, J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J. Allergy Clin. Immunol. 133, 429\u2013438 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR192","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jaip.2017.07.007","volume":"6","author":"C Goujon","year":"2018","unstructured":"Goujon, C. et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial. J. Allergy Clin. Immunol. Pract. 6, 562\u2013569.e3 (2018).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"703_CR193","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/bjd\/ljad281","volume":"189","author":"C Flohr","year":"2023","unstructured":"Flohr, C. et al. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial. Br. J. Dermatol. 189, 674\u2013684 (2023).","journal-title":"Br. J. Dermatol."},{"key":"703_CR194","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/bjd.21794","volume":"187","author":"D St\u00f6lzl","year":"2022","unstructured":"St\u00f6lzl, D. et al. Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry. Br. J. Dermatol. 187, 1022\u20131024 (2022).","journal-title":"Br. J. Dermatol."},{"key":"703_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.06.1574","author":"CG Bunick","year":"2025","unstructured":"Bunick, C. G. Biologic therapies targeting type 2 signaling in atopic dermatitis: a comparative review of structural and thermodynamic differences in mechanism of action. J. Invest. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2025.06.1574 (2025).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR196","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13555-023-00947-7","volume":"13","author":"AJ Okragly","year":"2023","unstructured":"Okragly, A. J. et al. Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab. Dermatol. Ther. 13, 1535\u20131547 (2023).","journal-title":"Dermatol. Ther."},{"key":"703_CR197","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020577","author":"RL Orfali","year":"2023","unstructured":"Orfali, R. L. & Aoki, V. Blockage of the Il-31 pathway as a potential target therapy for atopic dermatitis. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics15020577 (2023).","journal-title":"Pharmaceutics"},{"key":"703_CR198","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s13555-023-01000-3","volume":"13","author":"JI Silverberg","year":"2023","unstructured":"Silverberg, J. I. et al. Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis. Dermatol. Ther. 13, 2247\u20132264 (2023).","journal-title":"Dermatol. Ther."},{"key":"703_CR199","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","volume":"84","author":"AS Halling","year":"2021","unstructured":"Halling, A. S., Loft, N., Silverberg, J. I., Guttman-Yassky, E. & Thyssen, J. P. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J. Am. Acad. Dermatol. 84, 139\u2013147 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR200","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","volume":"152","author":"AWL Chu","year":"2023","unstructured":"Chu, A. W. L. et al. Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J. Allergy Clin. Immunol. 152, 1470\u20131492 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR201","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40257-023-00809-0","volume":"24","author":"JI Silverberg","year":"2023","unstructured":"Silverberg, J. I., Armstrong, A., Blauvelt, A. & Reich, K. Assessment of efficacy and safety outcomes beyond week 16 in clinical trials of systemic agents used for the treatment of moderate to severe atopic dermatitis in combination with topical corticosteroids. Am. J. Clin. Dermatol. 24, 913\u2013925 (2023).","journal-title":"Am. J. Clin. Dermatol."},{"key":"703_CR202","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1111\/jdv.17351","volume":"35","author":"JI Silverberg","year":"2021","unstructured":"Silverberg, J. I. et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J. Eur. Acad. Dermatol. Venereol. 35, 1797\u20131810 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR203","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg, A. et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br. J. Dermatol. 182, 1120\u20131135 (2020).","journal-title":"Br. J. Dermatol."},{"key":"703_CR204","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson, E. L. et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 156, 44\u201356 (2020).","journal-title":"JAMA Dermatol."},{"key":"703_CR205","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller, A. S. et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 400, 908\u2013919 (2022).","journal-title":"Lancet"},{"key":"703_CR206","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaad.2024.04.026","volume":"91","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay registry. J. Am. Acad. Dermatol. 91, 300\u2013311 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR207","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1111\/all.16147","volume":"79","author":"D St\u00f6lzl","year":"2024","unstructured":"St\u00f6lzl, D. et al. Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: results of the German TREATkids registry. Allergy 79, 2849\u20132852 (2024).","journal-title":"Allergy"},{"key":"703_CR208","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1111\/jdv.20699","volume":"39","author":"L Gargiulo","year":"2025","unstructured":"Gargiulo, L. et al. Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study. J. Eur. Acad. Dermatol. Venereol. 39, e807\u2013e811 (2025).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR209","first-page":"e756","volume":"39","author":"T Torres","year":"2025","unstructured":"Torres, T. et al. Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: an international, real-world comparative study. J. Eur. Acad. Dermatol. Venereol. 39, e756\u2013e761 (2025).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR210","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jamadermatol.2022.3014","volume":"158","author":"LS Spekhorst","year":"2022","unstructured":"Spekhorst, L. S. et al. Dupilumab drug survival and associated predictors in patients with moderate to severe atopic dermatitis: long-term results from the daily practice bioday registry. JAMA Dermatol. 158, 1048\u20131056 (2022).","journal-title":"JAMA Dermatol."},{"key":"703_CR211","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky, E. et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J. Allergy Clin. Immunol. 143, 155\u2013172 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR212","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1111\/all.15432","volume":"77","author":"E Berdyshev","year":"2022","unstructured":"Berdyshev, E. et al. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy 77, 3388\u20133397 (2022).","journal-title":"Allergy"},{"key":"703_CR213","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.jaci.2025.01.020","volume":"155","author":"E Goleva","year":"2025","unstructured":"Goleva, E. et al. Longitudinal integrated proteomic and metabolomic skin changes in patients with atopic dermatitis treated with dupilumab. J. Allergy Clin. Immunol. 155, 1536\u20131546 (2025).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR214","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaad.2024.11.079","volume":"92","author":"R Bissonnette","year":"2025","unstructured":"Bissonnette, R. et al. Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD). J. Am. Acad. Dermatol. 92, 1132\u20131136 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR215","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s13555-025-01357-7","volume":"15","author":"JI Silverberg","year":"2025","unstructured":"Silverberg, J. I. et al. Lebrikizumab vs other systemic monotherapies for moderate-to-severe atopic dermatitis: network meta-analysis of efficacy. Dermatol. Ther. 15, 615\u2013633 (2025).","journal-title":"Dermatol. Ther."},{"key":"703_CR216","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","volume":"160","author":"AM Drucker","year":"2024","unstructured":"Drucker, A. M. et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol. 160, 936\u2013944 (2024).","journal-title":"JAMA Dermatol."},{"key":"703_CR217","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.jid.2024.12.005","volume":"145","author":"R Tandon","year":"2025","unstructured":"Tandon, R. et al. Tralokinumab treatment of atopic dermatitis induces a progressive transcriptomic response. J. Invest. Dermatol. 145, 1643\u20131652.e13 (2025).","journal-title":"J. Invest. Dermatol."},{"key":"703_CR218","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/all.16108","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky, E. et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy 79, 1560\u20131572 (2024).","journal-title":"Allergy"},{"key":"703_CR219","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jaad.2022.11.047","volume":"88","author":"LA Beck","year":"2023","unstructured":"Beck, L. A. et al. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. J. Am. Acad. Dermatol. 88, 816\u2013823 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR220","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/bjd\/ljaf166","volume":"193","author":"AM Drucker","year":"2025","unstructured":"Drucker, A. M. et al. Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis. Br. J. Dermatol. 193, 548\u2013552 (2025).","journal-title":"Br. J. Dermatol."},{"key":"703_CR221","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.825312","volume":"13","author":"J Liang","year":"2022","unstructured":"Liang, J. et al. Safety and efficacy of nemolizumab for atopic dermatitis with pruritus: a systematic review and meta-regression analysis of randomized controlled trials. Front. Immunol. 13, 825312 (2022).","journal-title":"Front. Immunol."},{"key":"703_CR222","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1342810","volume":"15","author":"Q He","year":"2024","unstructured":"He, Q. et al. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses. Front. Immunol. 15, 1342810 (2024).","journal-title":"Front. Immunol."},{"key":"703_CR223","doi-asserted-by":"crossref","unstructured":"R\u00f8nnstad, A. T. M. et al. Real-world evidence of effectiveness and safety of abrocitinib, baricitinib and upadacitinib in atopic dermatitis: a systematic review and meta-analysis. Am. J. Clin. Dermatol. 27, 49\u201366 (2026).","DOI":"10.1007\/s40257-025-00997-x"},{"key":"703_CR224","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt, A. et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 157, 1047\u20131055 (2021).","journal-title":"JAMA Dermatol."},{"key":"703_CR225","doi-asserted-by":"crossref","unstructured":"Reich, K. et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet 400, 273\u2013282 (2022).","DOI":"10.1016\/S0140-6736(22)01199-0"},{"key":"703_CR226","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.41504","volume":"105","author":"AR Schlosser","year":"2025","unstructured":"Schlosser, A. R., Nijman, L., Schappin, R., Nijsten, T. E. C. & Hijnen, D. Long-term outcomes of new systemic agents in atopic dermatitis: drug survival analyses and treatment patterns in daily practice. Acta Derm. Venereol. 105, adv41504 (2025).","journal-title":"Acta Derm. Venereol."},{"key":"703_CR227","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1658843","volume":"12","author":"A Prados-Carmona","year":"2025","unstructured":"Prados-Carmona, A., Navarro Trivi\u00f1o, F. J., Husein-ElAhmed, H. & Ruiz-Villaverde, R. Comparative real-world effectiveness and safety of biologics and JAK inhibitors in atopic dermatitis: short- and medium-to-long-term analysis from a regional healthcare network in southern Spain. Front. Med. 12, 1658843 (2025).","journal-title":"Front. Med."},{"key":"703_CR228","doi-asserted-by":"crossref","unstructured":"van der Gang, L. F. et al. Drug survival in atopic dermatitis: comparison of biologics and JAK inhibitors in the BioDay registry. Allergy 81, 609\u2013613 (2025).","DOI":"10.1111\/all.70187"},{"key":"703_CR229","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.19426","volume":"38","author":"S Yoon","year":"2024","unstructured":"Yoon, S. et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J. Eur. Acad. Dermatol. Venereol. 38, 52\u201361 (2024).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR230","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jaci.2024.07.019","volume":"154","author":"SY Tsai","year":"2024","unstructured":"Tsai, S. Y. et al. Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: a population-based cohort study. J. Allergy Clin. Immunol. 154, 1195\u20131203.e3 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR231","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).","journal-title":"N. Engl. J. Med."},{"key":"703_CR232","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","volume":"160","author":"JP Ingrassia","year":"2024","unstructured":"Ingrassia, J. P. et al. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 160, 28\u201336 (2024).","journal-title":"JAMA Dermatol."},{"key":"703_CR233","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2474507","volume":"36","author":"X Su","year":"2025","unstructured":"Su, X. et al. Risk of serious infection with JAK inhibitors in immune-mediated inflammatory skin diseases: a meta-analysis of randomized clinical trials. J. Dermatol. Treat. 36, 2474507 (2025).","journal-title":"J. Dermatol. Treat."},{"key":"703_CR234","first-page":"223","volume":"159","author":"G Argenziano","year":"2024","unstructured":"Argenziano, G. et al. Italian S3-guideline on the treatment of atopic eczema \u2014 part 1: systemic therapy, adapted from EuroGuiDerm by the italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA). Ital. J. Dermatol. Venerol. 159, 223\u2013250 (2024).","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"703_CR235","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/bjd\/ljae342","volume":"192","author":"C Haag","year":"2024","unstructured":"Haag, C. et al. A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council. Br. J. Dermatol. 192, 135\u2013143 (2024).","journal-title":"Br. J. Dermatol."},{"key":"703_CR236","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jaad.2023.04.052","volume":"89","author":"JI Silverberg","year":"2023","unstructured":"Silverberg, J. I. et al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM AD cohort. J. Am. Acad. Dermatol. 89, 519\u2013528 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR237","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jaad.2023.12.066","volume":"90","author":"EL Simpson","year":"2024","unstructured":"Simpson, E. L. et al. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 90, 1190\u20131199 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"703_CR238","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05958407 (2026)."},{"key":"703_CR239","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06921759 (2026)."},{"key":"703_CR240","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jaip.2025.04.042","volume":"13","author":"M Kamata","year":"2025","unstructured":"Kamata, M., Sun, D. I. & Paller, A. S. Deciding which patients with atopic dermatitis to prioritize for biologics and Janus kinase inhibitors. J. Allergy Clin. Immunol. Pract. 13, 1901\u20131910.e1 (2025).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"703_CR241","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/j.1365-2133.2008.08756.x","volume":"159","author":"D Cicek","year":"2008","unstructured":"Cicek, D. Does autonomic dysfunction play a role in atopic dermatitis?\u00a0Br. J. Dermatol. 159, 834\u2013838 (2008).","journal-title":"Br. J. Dermatol."},{"key":"703_CR242","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1183\/09031936.95.08030483","volume":"8","author":"MI Asher","year":"1995","unstructured":"Asher, M. I. International study of asthma and allergies in childhood (ISAAC): rationale and methods. Eur. Respir. J. 8, 483\u2013491 (1995).","journal-title":"Eur. Respir. J."},{"key":"703_CR243","volume":"8","author":"H Singleton","year":"2024","unstructured":"Singleton, H. et al. Educational and psychological interventions for managing atopic dermatitis (eczema). Cochrane Database Syst. Rev. 8, Cd014932 (2024).","journal-title":"Cochrane Database Syst. Rev."},{"key":"703_CR244","doi-asserted-by":"crossref","unstructured":"Finlay, A. Y. & Khan, G. K. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210\u2013216 (1994).","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"703_CR245","doi-asserted-by":"crossref","unstructured":"Lewis-Jones, M. S. & Finlay, A. Y. The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br. J. Dermatol. 132, 942\u2013949 (1995).","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"703_CR246","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00403-021-02282-3","volume":"314","author":"R Chovatiya","year":"2022","unstructured":"Chovatiya, R., Begolka, W. S., Thibau, I. J. & Silverberg, J. I. Financial burden and impact of atopic dermatitis out-of-pocket healthcare expenses among Black individuals in the United States. Arch. Dermatol. Res. 314, 739\u2013747 (2022).","journal-title":"Arch. Dermatol. Res."},{"key":"703_CR247","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/jdv.15634","volume":"33","author":"J Ring","year":"2019","unstructured":"Ring, J. et al. Atopic eczema: burden of disease and individual suffering \u2014 results from a large EU study in adults. J. Eur. Acad. Dermatol. Venereol. 33, 1331\u20131340 (2019).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR248","doi-asserted-by":"publisher","first-page":"463","DOI":"10.5664\/jcsm.8234","volume":"16","author":"MA Gupta","year":"2020","unstructured":"Gupta, M. A. & Gupta, A. K. An elevated leg movement index during sleep in atopic dermatitis and periodic leg movement disorder may be an indication of sympathetic activation common to both. J. Clin. Sleep. Med. 16, 463\u2013463 (2020).","journal-title":"J. Clin. Sleep. Med."},{"key":"703_CR249","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/j.jaci.2022.03.017","volume":"149","author":"HC Williams","year":"2022","unstructured":"Williams, H. C. et al. The HOME core outcome set for clinical trials of atopic dermatitis. J. Allergy Clin. Immunol. 149, 1899\u20131911 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR250","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0140-6736(19)32984-8","volume":"395","author":"JR Chalmers","year":"2020","unstructured":"Chalmers, J. R. et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet 395, 962\u2013972 (2020).","journal-title":"Lancet"},{"key":"703_CR251","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/S0140-6736(22)00687-0","volume":"399","author":"HO Skjerven","year":"2022","unstructured":"Skjerven, H. O. et al. Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet 399, 2398\u20132411 (2022).","journal-title":"Lancet"},{"key":"703_CR252","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamadermatol.2025.2357","volume":"161","author":"EL Simpson","year":"2025","unstructured":"Simpson, E. L. et al. Emollients to prevent pediatric eczema: a randomized clinical trial. JAMA Dermatol. 161, 957\u2013965 (2025).","journal-title":"JAMA Dermatol."},{"key":"703_CR253","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","volume":"22","author":"T Bieber","year":"2023","unstructured":"Bieber, T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat. Rev. Drug. Discov. 22, 662\u2013680 (2023).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"703_CR254","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber, T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat. Rev. Drug. Discov. 21, 21\u201340 (2022).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"703_CR255","unstructured":"Apogee Therapeutics. Apogee Therapeutics announces positive 16-week data from phase 2 APEX clinical trial of APG777, its potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis. Apogee Therapeutics News Releases https:\/\/go.nature.com\/4dpewfr (7 July 2025)."},{"key":"703_CR256","unstructured":"Businesswire. LEO Pharma announces positive topline phase 2b results for temtokibart in moderate-to-severe atopic dermatitis. Businesswire Newsroom https:\/\/go.nature.com\/4fnh5kC (9 May 2025)."},{"key":"703_CR257","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s40265-024-02095-4","volume":"84","author":"JM Alvarenga","year":"2024","unstructured":"Alvarenga, J. M., Bieber, T. & Torres, T. Emerging biologic therapies for the treatment of atopic dermatitis. Drugs 84, 1379\u20131394 (2024).","journal-title":"Drugs"},{"key":"703_CR258","unstructured":"Kyowa Kirin. Kyowa Kirin announces discontinuation of rocatinlimab clinical trials. Kyowa Kirin News Releases https:\/\/go.nature.com\/4wFa5Gi (3 March 2026)."},{"key":"703_CR259","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-026-01453-7","author":"T Li","year":"2026","unstructured":"Li, T. et al. Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies. Blood Cancer J. https:\/\/doi.org\/10.1038\/s41408-026-01453-7 (2026).","journal-title":"Blood Cancer J."},{"key":"703_CR260","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06945458 (2026)."},{"key":"703_CR261","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53384-1","volume":"15","author":"JI Silverberg","year":"2024","unstructured":"Silverberg, J. I. et al. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nat. Commun. 15, 9230 (2024).","journal-title":"Nat. Commun."},{"key":"703_CR262","unstructured":"UCB. UCB announces successful first-in-patient trial for galvokimig in moderate-to-severe atopic dermatitis at EADV. UCB Newsroom https:\/\/go.nature.com\/4nrjBZi (18 September 2025)."},{"key":"703_CR263","unstructured":"Businesswire. Pfizer\u2019s phase 2 study of trispecific antibody positive in moderate to severe atopic dermatitis. Businesswire Newsroom https:\/\/go.nature.com\/4nmBxnQ (9 March 2026)."},{"key":"703_CR264","unstructured":"LaHucik, K. J&J discontinues work on eczema drug, leading to $610M impairment charges for ex-XBiotech asset. Fierce Biotech https:\/\/go.nature.com\/4u83KkM (2 February 2022)."},{"key":"703_CR265","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06130566 (2025)."},{"key":"703_CR266","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06181435 (2026)."},{"key":"703_CR267","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05769777 (2026)."},{"key":"703_CR268","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05932654 (2025)."},{"key":"703_CR269","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05694884 (2024)."},{"key":"703_CR270","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06383468 (2024)."},{"key":"703_CR271","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06136741 (2026)."},{"key":"703_CR272","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05923099 (2026)."},{"key":"703_CR273","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07003425 (2026)."},{"key":"703_CR274","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07223697 (2026)."},{"key":"703_CR275","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06863961 (2026)."},{"key":"703_CR276","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06727552 (2026)."},{"key":"703_CR277","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06436183 (2025)."},{"key":"703_CR278","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06723405 (2025)."},{"key":"703_CR279","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05059509 (2022)."},{"key":"703_CR280","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07027527 (2026)."},{"key":"703_CR281","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06787586 (2026)."},{"key":"703_CR282","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06248814 (2025)."},{"key":"703_CR283","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07277660 (2026)."},{"key":"703_CR284","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07230483 (2025)."},{"key":"703_CR285","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06790121 (2026)."},{"key":"703_CR286","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05995964 (2026)."},{"key":"703_CR287","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06808477 (2025)."},{"key":"703_CR288","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06716879 (2026)."},{"key":"703_CR289","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04539639 (2023)."},{"key":"703_CR290","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07217015 (2026)."},{"key":"703_CR291","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07441395 (2026)."},{"key":"703_CR292","doi-asserted-by":"publisher","unstructured":"ISRCTN. ISRCTN https:\/\/doi.org\/10.1186\/ISRCTN80838388 (2025).","DOI":"10.1186\/ISRCTN80838388"},{"key":"703_CR293","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02748993 (2018)."},{"key":"703_CR294","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05432596 (2024)."},{"key":"703_CR295","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04313400 (2025)."},{"key":"703_CR296","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04717310 (2023)."},{"key":"703_CR297","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/bjd.18643","volume":"182","author":"H Alexander","year":"2019","unstructured":"Alexander, H. et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. Br. J. Dermatol. 182, 1331\u20131342 (2019).","journal-title":"Br. J. Dermatol."},{"key":"703_CR298","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","volume":"67","author":"ME Schram","year":"2012","unstructured":"Schram, M. E. et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 67, 99\u2013106 (2012).","journal-title":"Allergy"},{"key":"703_CR299","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-019-0095-3","volume":"19","author":"E Simpson","year":"2019","unstructured":"Simpson, E. et al. Validation of the atopic dermatitis control tool (ADCT\u00a9) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 19, 15 (2019).","journal-title":"BMC Dermatol."},{"key":"703_CR300","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/bjd.18780","volume":"183","author":"LM Howells","year":"2020","unstructured":"Howells, L. M. et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of Atopic Eczema (RECAP). Br. J. Dermatol. 183, 524\u2013536 (2020).","journal-title":"Br. J. Dermatol."},{"key":"703_CR301","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631\u2013637 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"703_CR302","doi-asserted-by":"publisher","unstructured":"Merola. J. F. et al. International Eczema Council definitions of low disease activity and remission in atopic dermatitis: a consensus statement. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2026.0662 (2026).","DOI":"10.1001\/jamadermatol.2026.0662"},{"key":"703_CR303","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jaci.2013.12.1079","volume":"133","author":"TS Tang","year":"2014","unstructured":"Tang, T. S., Bieber, T. & Williams, H. C. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful?\u00a0J. Allergy Clin. Immunol. 133, 1615\u20131625.e1 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"703_CR304","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/jdv.19699","volume":"38","author":"ME Jacobson","year":"2024","unstructured":"Jacobson, M. E. et al. Early intervention and disease modification in atopic dermatitis-the current state of the field and barriers to progress. J. Eur. Acad. Dermatol. Venereol. 38, 665\u2013672 (2024).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"703_CR305","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/j.jaip.2025.02.013","volume":"13","author":"HC Williams","year":"2025","unstructured":"Williams, H. C., Simpson, E. L., Langan, S. M., Roberts, A. & Thomas, K. S. Achieving long-term control in atopic dermatitis: emerging concepts, definitions, flares, and therapy. J. Allergy Clin. Immunol. Pract. 13, 1912\u20131914.e2 (2025).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"703_CR306","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1089\/derm.2024.0121","volume":"36","author":"S Narla","year":"2025","unstructured":"Narla, S. et al. What does long-term control in atopic dermatitis look like?\u00a0Dermatitis 36, 583\u2013600 (2025).","journal-title":"Dermatitis"},{"key":"703_CR307","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s13555-024-01110-6","volume":"14","author":"E Vakirlis","year":"2024","unstructured":"Vakirlis, E. et al. Insights into early systemic treatment in atopic dermatitis: scientific facts and practical considerations. Dermatol. Ther. 14, 563\u2013568 (2024).","journal-title":"Dermatol. Ther."},{"key":"703_CR308","doi-asserted-by":"publisher","DOI":"10.1111\/all.70036","author":"T Bieber","year":"2025","unstructured":"Bieber, T., Maintz, L., Phad, G. E. & Br\u00fcggen, M. C. From disease control to disease modification: the Atopic Dermatitis Disease Activity Index. Allergy https:\/\/doi.org\/10.1111\/all.70036 (2025).","journal-title":"Allergy"}],"updated-by":[{"DOI":"10.1038\/s41572-026-00721-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000}}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00703-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00703-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00703-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:04:19Z","timestamp":1781870659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00703-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":308,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1038\/s41572-026-00703-z","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"20 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41572-026-00721-x","URL":"https:\/\/doi.org\/10.1038\/s41572-026-00721-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.W. has received consulting fees, honoraria, grant support and\/or lecture fees from AbbVie, Almirall, Apogee, Astria, Boehringer, Eli Lilly, Galderma, GSK, LEO Pharma, Pfizer, Regeneron Pharmaceuticals, Sanofi and UCB. V.A. has acted as an advisor for Galderma and Sanofi; and an investigator for AMGEN and Abbvie. N.C.D. received an honorarium or conducted clinal trials, and\/or was a member of the advisory board, for Beiersdorf, L\u2019or\u00e9al, Galderma, Piere Fabre, Sanofi and Aventis. S.D. was a member of the advisory board of Galderma, Sanofi and Cipla Immunology, with honoraria. K.K. has received consulting fees, honoraria, grant support and\/or lecture fees from AbbVie, Amgen, Eli Lilly, Kyowa Kirin, Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe, Ono Pharmaceutical, Pfizer, Procter & Gamble, Sanofi, Regeneron\u00a0Pharmaceuticals, Taiho and Torii Pharmaceutical. L.M. has received research support and fees for consulting or as a speaker on atopic dermatitis from Regeneron\u00a0Pharmaceuticals, Sanofi, Pfizer, Galderma, Leo Pharma, Janssen, Abbvie, Batanee and thederma, and declares no patents, ownership or financial gain from any atopic dermatitis drug. C.F. has received consulting fees, honoraria, grant support, and\/or lecture fees from AbbVie, Almirall, Amgen, Apogee, Bioderma, LEO Pharma, Medac, Pfizer, Sanofi and Regeneron\u00a0Pharmaceuticals. A.D.I. has acted as a consultant for AbbVie, Arena Pharmaceuticals, Dermavant, Eli Lilly, LEO Pharma, Menlo Therapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sitryx and UCB; has received speaker fees from AbbVie, Eli Lilly, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi; has acted as an investigator for AbbVie, Novartis and Sanofi-Regeneron Pharmaceuticals\u00a0and Sanofi; and is a patent holder with Regeneron Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}